Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumors

scientific article published on 15 December 2008

Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumors is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1200/JCO.2008.17.6644
P932PMC publication ID2645861
P698PubMed publication ID19075272

P50authorFrank BalisQ38641035
Tito FojoQ89148742
P2093author name stringElizabeth Fox
Brigitte C Widemann
Anne Goodwin
Wendy Goodspeed
P2860cites workEpothilones: mechanism of action and biologic activityQ28261744
Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomasQ28285708
Phase I trial of docetaxel with filgrastim support in pediatric patients with refractory solid tumors: a collaborative Pediatric Oncology Branch, National Cancer Institute and Children's Cancer Group trialQ33328543
Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.Q33369363
Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trialQ33499553
Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action.Q34722347
In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer modelsQ40366025
A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors.Q40472146
Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days.Q42440513
Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumorsQ44772606
Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.Q45285635
A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days.Q46413137
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancerQ46443846
The epothilone dilemma.Q50952412
A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxaneQ56786884
Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast CancerQ58614874
Phase II Trial of Ixabepilone, an Epothilone B Analog, in Patients With Metastatic Breast Cancer Previously Untreated With TaxanesQ61624860
Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological propertiesQ71236147
Accelerated titration designs for phase I clinical trials in oncologyQ73598986
Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumorsQ80532879
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapyQ80558321
Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapyQ80558327
Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabineQ80558331
P433issue4
P407language of work or nameEnglishQ1860
P921main subjectpharmacokineticsQ323936
teenagerQ1492760
phase I clinical trialQ5452194
ixabepiloneQ11711607
P304page(s)550-556
P577publication date2008-12-15
P1433published inJournal of Clinical OncologyQ400292
P1476titlePhase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumors
P478volume27

Reverse relations

cites work (P2860)
Q38961012A comparison of safety and efficacy of cytotoxic versus molecularly targeted drugs in pediatric phase I solid tumor oncology trials
Q39878337Adaptive dose modification for phase I clinical trials.
Q33520467Angiogenesis and vascular targeting in Ewing sarcoma: a review of preclinical and clinical data
Q35958048Comprehensive analysis of published phase I/II clinical trials between 1990-2010 in osteosarcoma and Ewing sarcoma confirms limited outcomes and need for translational investment
Q37048013Phase I and Phase II Objective Response Rates are Correlated in Pediatric Cancer Trials: An Argument for Better Clinical Trial Efficiency
Q39555847Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.
Q34915389Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology group
Q88993176Rethinking medulloblastoma from a targeted therapeutics perspective
Q54559815Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma.
Q39432147Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth
Q42170353Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152).
Q47559320Voices of children and adolescents on phase 1 or phase 2 cancer trials: A new trial endpoint?